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survey contained demographic, disease characteristic and health care experience 
variables, which were evaluated as potential predictors of DMD adherence using 
logistic regression, controlling for age and gender. No adjustment was made for 
multiplicity. Results: 969 patients completed the survey; 579 met analysis crite-
ria. High vs. intermediate/low adherers represented 47.7% and 52.3%, respectively. 
Average age for high adherers was 49.1 (SD: 10.9), 81.5% female; intermediate/
low adherers had an average age of 47.3 (SD: 11.4), 87.7% female. Of 149 variables, 
the following were associated with greater odds of high adherence: detailed dis-
cussions with health care professional about “how long the treatment had been 
available” (p= 0.02; OR: 1.47; high 56.8% vs. intermediate/low 47.1%) or “long-term 
safety” (p= 0.01; OR: 1.54; high 54.8% vs. intermediate/low 44.2%); satisfaction with 
DMD (p= 0.04; OR: 1.14; high 5.4 [SD: 1.4] vs. intermediate/low 5.2 [SD: 1.3] ); or 
insurance covered entire cost of DMD (p= 0.01; OR: 1.71; high 23.1% vs. intermedi-
ate/low 15.2%). Results indicating lower odds of high adherence included longer 
duration on current therapy (p< 0.01; OR: 0.99; high 63.2 [SD: 53.5] months vs. inter-
mediate/low 75.9 [SD: 60.0] months) and cost made them “skip a dose” (p< 0.01; 
OR: 0.37; high 5.3% vs. intermediate/low 13.4%) or “not fill or refill a prescription” 
(p< 0.01; OR: 0.43; high 5.3% vs. intermediate/low 12.0%). ConClusions: Patient 
and provider dialogue, patient satisfaction with treatment and health plan benefit 
design aspects may affect DMD adherence.
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MoDelliNg the PersisteNce of Disease-MoDifyiNg Drug treatMeNt 
(DMt) aND its iNDePeNDeNt Drivers iN fiNNish MultiPle sclerosis (Ms) 
PatieNts: ParaMetric survival MoDelliNg
Soini E.1, Holmberg M.2, Asseburg C.1, Sumelahti M.L.2
1ESiOR Oy, Kuopio, Finland, 2School of Medicine, University of Tampere, Finland
objeCtives: Explore how MS DMT-persistence can be modelled, compare model’s 
performance and assess the independent drivers for DMT-persistence. Methods: 
Analysis was based on 1638 DMT uses (1.1. 1991–31.12.2010, time at risk 4009 years) 
in incident MS-patient register from Tampere, Vaasa and Seinäjoki regions, Finland. 
DMT-persistence = DMT end-day - DMT initiation day. Cox, exponential, general-
ized gamma, Gompertz, log-logistic, log-normal, and Weibull regression survival 
models were used to model DMT-persistence. Models were compared based on 
goodness-of-fit statistics (Akaike and Bayesian information criteria). Results: 
Mean follow-up from first MS-symptoms and age at first DMT-initiation were 13 
and 36 years, respectively. 73% of patients were female. Based on the data explo-
ration of all known covariates, three DMT-persistence approaches with different 
interpretations, selected covariates and data needs were modelled: 1] sex, birth 
year, time from symptoms to DMT, age, DMT line (1st, 2nd, 3rd, 4th, 5-7th), DMT 
(interferon-β -1a and -1b, glatiramer acetate, other) at DMT initiation; 2] approach 
1] + Expanded Disability Status Scale (EDSS) at DMT initiation; and 3] approach 2] 
+ DMT-discontinuation reason (pregnancy plan, flu-like symptoms, injection-site 
reactions, ineffectiveness, antibodies, other/unknown). There was no gold stand-
ard survival model for DMT-persistence, and some models accommodated higher 
number of covariates and associated dependencies better. For approaches 1] and 
2] Weibull and for 3] Gompertz model provided the best goodness-of-fit. Based on 
all three models (one per approach 1] –3]) with best goodness-of-fit, higher EDSS 
or higher age at DMT initiation, treatment line (3rd and later), and incidence of 
intolerable adverse events (AE) or ineffectiveness were independently associated 
with shorter DMT persistence. In the approach 3], flu-like symptom and injection 
site AEs had the highest hazard ratio for shorter DMT-persistence. ConClusions: 
AEs, EDSS, age, treatment line and ineffectiveness were strong predictors for DMT-
persistence. Flu-like symptoms and injection site AEs showed the highest hazard 
for DMT-discontinuation.
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objeCtives: To compare 6-month persistence rates among patients initiating the 
oral multiple sclerosis (MS) disease-modifying therapies (DMTs) fingolimod and 
dimethyl fumarate (DMF). Methods: Our retrospective analysis used mail-order 
pharmacy claims from the US open-source LRx™ database (IMS). Patients with ≥ 1 
fingolimod or DMF prescription (index DMT) between 01-April-2013 and 31-July-
2013 were included. Patients were ≥ 18 years old, naive to fingolimod and DMF, and 
had not received multiple DMTs on the date of the first index DMT claim (index 
date). Prescription records were collected from pharmacies supplying ≥ 1 index 
DMT claim between the index date and the last month of follow-up. Persistence 
was assessed as time from initiating index DMT until discontinuation (gap of ≥ 60 
days), receipt of another DMT or the end of the 6-month follow-up period. The 
risk of and time to index DMT discontinuation was assessed using a Cox propor-
tional hazards model (controlling for age, gender and region) and Kaplan-Meier 
analysis, respectively. Results: The study included 9546 patients (fingolimod: 
n= 1390; DMF: n= 8156). The proportion of patients discontinuing index DMT was 
significantly lower for patients receiving fingolimod (23.3%) versus DMF (36.6%; 
p< 0.0001). The risk of discontinuation was 1.6-fold higher in the DMF cohort ver-
sus the fingolimod cohort (hazard ratio, 95% confidence intervals: 1.58, 1.41-1.77; 
p< 0.0001). Time to discontinuation was significantly longer with fingolimod than 
with DMF (p< 0.0001), resulting in a longer duration of therapy persistence for 
fingolimod versus DMF (mean ± standard deviation: 152±53 days versus 135±62 
days, respectively). Results were similar when discontinuation was defined as a 
gap of ≥ 30 days (p< 0.0001 for all outcomes). ConClusions: This analysis provides 
the first insight into short-term persistence rates with oral DMTs. In a real-world 
setting, the risk of discontinuation over 6 months was lower for patients initiating 
fingolimod versus DMF.
QALY gained. However, SA results indicate that the ICER drops below this threshold 
when most current clinical practice at the cited center is considered. Moreover, SA 
results suggest potential ways to optimize the current clinical pathway in order 
to reduce procedure costs even further.
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loNg-terM costs aND coNsequeNces of PatieNts with faMilial 
chyloMicroNeMia syNDroMe – a siMulatioN MoDel aPProach
Lin F., Thomas S., Calado F., Clegg J.
Novartis, East Hanover, NJ, USA
bACkgRound: Familial chylomicronemia syndrome (FCS) is a rare genetic dis-
order characterized by deficiency of lipoprotein lipase, causing accumulation of 
chylomicrons. An estimated 0.1-0.2 per 100,000 people has FCS worldwide. FCS 
patients present massively elevated triglyceride levels (typically > 2,000 mg/dL), 
resulting in increased risk of recurring acute pancreatitis. Standard triglyceride 
lowering medications are ineffective for FCS patients, who rely on restrictive 
low fat diet to control their triglyceride. There is limited literature about long-
term progression, the burden of illness or consequences of acute pancreatitis for 
FCS. objeCtives: To estimate long term disease progression, costs and conse-
quences of FCS. Methods: An individual Monte Carlo simulation model was built 
to track disease progression of a cohort of FCS patients with a mean age of 37.8 
years, 60% male, and a mean triglyceride level of 2,741 mg/dL. The model projected 
the number of acute pancreatitis events, mortality and medical costs. Benefits 
of a hypothetical triglyceride reduction intervention were assessed. Results: 
With standard diet control, the average life expectancy of the studied cohort was 
estimated to be 16.45 years. These patients were expected to experience 10.16 
episodes of acute pancreatitis during their lifetime, resulting in 80.7 inpatient days. 
The discounted lifetime cost of acute pancreatitis was projected to be $154,126 
per patient. The cumulative mortality due to acute pancreatitis was estimated to 
be 54.3%. Should an intervention reduce triglyceride levels by 50% in FCS patients, 
the life expectancy would be increased by 3.16 years and 7.72 fewer episodes of 
acute pancreatitis would occur, preventing 61.21 inpatient days and saving 
$118,594 in medical cost. ConClusions: FCS patients are at high risk of life-
threatening and costly acute pancreatitis. Reduction in triglyceride levels has a 
significant impact of morbidity and mortality associated with acute pancreatitis. 
An effective triglyceride lowering intervention could mitigate the consequences 
of FCS significantly.
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workiNg ability aND MoNetarily valueD ProDuctivity of PatieNts 
with MultiPle sclerosis treateD with NatalizuMab
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objeCtives: Relapsing remitting multiple sclerosis (RRMS) is a chronic inflam-
matory disease that represents the most common chronic neurological disorder 
in young adults. RRMS often leads to disability and is a major cause of reduced 
working capacity due to neurological diseases. Aim of this study is to investigate 
patients’ working productivity during treatment with natalizumab. Methods: 
RRMS-Patients treated with natalizumab for a maximum of three months prior to 
baseline were eligible for study participation. Patients completed the EQ-5D and 
a questionnaire focused on occupational status, working ability, and days absent 
from work at study start study, after 6 months and 12 months. Socio-demographic 
and clinical data were collected. Primary endpoint was work productivity, which 
is defined as hours worked. To estimate costs and cost offsets due to the therapy 
with natalizumab, an average monetary value per working hour has been calcu-
lated to value productivity monetarily. Results: Preliminary results including 95 
patients after 6 months of therapy show a significant increase in work productivity 
of 84 hours (p= 0.014) for the whole study population compared to baseline. The 
average reduction of days absent from work was 4.8 days compared to baseline. 
The increase in working hours leads to an average change of monetarily valued 
productivity per patient and half-year from 6,550.40€ at baseline to 7,600.35€ after 
6 months for the entire study population. A subgroup analysis has been run on 
the group of employed patients. The working hours increased significantly by 
63h per half-year (p= 0.025). ConClusions: In this study, the preliminary results 
show a significant increase in work productivity, which leads to a significant 
increase in the monetary value of productivity, for RRMS-patients treated with 
natalizumab. An increase in working hours as well as a decrease in days absent 
from work led to an increase in monetarily valued productivity. Study was funded 
by Biogen-Idec.
Neurological DisorDers – Patient-reported outcomes & Patient Preference 
studies
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Phillips A.L.1, Kozma C.M.2, Locklear J.C.1
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objeCtives: Identify predictors of multiple sclerosis (MS) disease-modifying drug 
(DMD) adherence. Methods: A random sample of adult MS patients from the US 
National Health and Wellness Survey or Lightspeed Research panel completed an 
internet survey in Nov/Dec2012. Clinical trial–naïve subjects with relapsing-remit-
ting MS who were on their current DMD for ≥ 4months were included. Adherence 
was measured using the 4-item Morisky Scale. Patients were assigned to ‘high’ 
(negative response to all 4 questions: forget to take, careless at times about tak-
ing, stop if better, stop if worse) or ‘intermediate/low’ (any positive response). The 
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within the four questions. Respondents were willing to sacrifice median 5 and 
8 years of their remaining lifespan until the age of 80 years for avoiding two 
migraines per month and per week, respectively. Mean utilities for two migraines 
each month were U20m= 0.84 (SD 0.26) and U80m= 0.89 (SD 0.14), and for each 
week were U20w= 0.79 (SD 0.27) and U80w= 0.83 (SD 0.17), respectively. Self-reported 
migraneurs elicited higher mean utilities compared to non-migraneurs for all 
migraine health states but this difference was statistically significant only for 
U80m (p= 0.039). Also, males attached lower mean utilities for all health states 
than females but this was significant only for U80m (p= 0.018). Besides, older 
respondents valued higher mean utilities for U20m compared to the younger ones 
(p= 0.040). ConClusions: Our findings provide the first time trade-off utilities 
on migraine associated HRQOL impairment. Disutility caused by migraine ranged 
between 0.1 and 0.2 depending on attack frequency.
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huMaNistic research outcoMes iN MultiPle sclerosis: review of the 
literature froM latiN aMerica
Einarson T.R.1, Bereza B.1, Machado M.2
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objeCtives: This research reviews the research literature reporting humanistic 
outcomes related to multiple sclerosis (MS) in Latin America. Methods: We con-
ducted a systematic search of Medline, Embase, LILACS and Scielo from inception 
through 2013 for articles reporting original research on quality of life (QoL), utility 
scores for states of MS, patient preference, mental health, social and emotional 
wellbeing in people with MS in Latin America. Adherence and related issues were 
not included. Outcomes were categorized into: mental domain (cognitive function; 
mental health), physical domain (mobility/independence; fatigue; restless legs syn-
drome), employment, QoL, caregiver burden, and patient preference. Results: A 
total of 38 studies were selected for analysis. Among them, 23 addressed issues in 
the mental domain (9 cognitive functions and 14 mental health), 41 in the physical 
domain (24 mobility/physical function, 15 fatigue and 2 restless legs syndrome). 
One addressed impact of MS on employment, 16 QoL, 2 caregiver burden and 1 
patient preference. Researchers used 56 different instruments to collect their data 
from 2286 patients. Compared with controls, MS patients had significantly (P< 0.05) 
lower levels of functioning, cognition and increased presence of mental illness. All 
of these factors were significantly associated with decreased QoL in patients (odds 
ratios ranged from 4.2-10.1; P< 0.05). Similarly, fatigue and restless legs syndrome 
correlated significantly with anxiety, depression and level of mobility/functioning as 
well as QoL. ConClusions: As in other parts of the world, MS exerts a substantial 
negative impact on the lives of people with MS in Latin America. It lowers their QoL 
and interferes with their ability to move about, care for themselves and work. Their 
social life is also negatively affected. The amount of literature on this subject is 
quite limited. More research in Latin America is needed to understand humanistic 
outcomes in these patients and management of their MS.
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objeCtives: The aims of this study were to quantify the burden of insomnia and 
to quantify the association between side effects of insomnia medications and 
health outcomes. Methods: Data from the 2013 US (N= 75,000) and 5EU (N= 62,000) 
National Health and Wellness Survey (NHWS) were used. The NHWS is a patient-
reported survey administered to a demographically representative sample of adults 
(with respect to age, sex, race/ethnicity, and region). Those who met DSM-V criteria 
for insomnia and, separately, those treated with insomnia were compared with their 
respective propensity score-matched control groups on health status (SF-36v2), work 
productivity (WPAI-GH), and health care resource use using ANOVA tests. Among 
those with treated insomnia, those with and without side effects were compared on 
health outcomes using general linear models controlling for demographics, health 
history, and comorbidities. Results: Compared with their respective matched con-
trol groups, patients with insomnia (n= 4147) and treated insomnia (n= 2860) in the 
5EU reported significantly worse mean health utilities (0.60 vs. 0.74; 0.60 vs. 0.74, 
respectively), greater overall work impairment (38.74% vs. 14.86%; 39.50% vs. 15.66%), 
and more annual physician visits (9.10 vs. 4.08; 9.58 vs. 4.11). Similar findings were 
observed in the US cohort. Among those treated for insomnia, 13.56% and 24.55% 
in the US and 5EU, respectively, were non-adherent due to side effects. In the US, 
this behavior was associated with significantly worse health utilities (0.60 vs. 0.64) 
and greater overall work impairment (37.71% vs. 29.08%), among other variables 
(all p< .05). These relationships were not significant in the 5EU. ConClusions: A 
significant humanistic and economic burden of insomnia was observed in both the 
US and 5EU, and the burden remains even after treatment. Non-adherence due to 
side effects was common and, in the case of the US, associated with significantly 
poorer health outcomes.
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quality of life aMoNg PatieNts with MultiPle sclerosis treateD 
with ProloNgeD-release faMPriDiNe 10 Mg tablets for walkiNg 
iMPairMeNt
Liu Y.1, McNeill M.2, Lee A.1, Zhong J.1, Mehta L.R.1
1Biogen Idec, Cambridge, MA, USA, 2Biogen Idec, Maidenhead, UK
objeCtives: To evaluate the effect of prolonged-release (PR) fampridine 10 mg 
tablet on generic quality of life (QoL) as measured by the EQ-5D in patients with 
multiple sclerosis (MS) with walking impairment. Methods: The study popula-
tion included 132 patients who enrolled in a 24-week randomized, double-blind, 
and placebo-controlled phase 2 trial (NCT01597297) of PR-fampridine 10 mg tab-
lets or placebo twice daily in multiple sites in Europe and Canada. Patients were 
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objeCtives: To compare 6-month persistence rates among patients receiving the 
multiple sclerosis (MS) disease-modifying therapies (DMTs) fingolimod or interferon/
glatiramer acetate (IFN/GA) (index DMT), using open- and closed-source data that 
reflect unrestricted or continuous health care coverage, respectively. Methods: 
Retrospective analyses used administrative claims and mail-order pharmacy data-
bases (IMS PharMetrics Plus™ [closed]) and LRx™ [open], respectively). All patients 
were ≥ 18 years old and naive to fingolimod and index DMT, had ≥ 1 prescription for 
index DMT between 01-Oct-2010 and 31-Mar-2013 and had not received multiple 
DMTs at index date. An additional PharMetrics cohort was selected using more 
stringent criteria (continuous enrolment pre-/post-index; MS diagnosis code). 
LRx prescriptions were collected from pharmacies supplying ≥ 1 claim for index 
DMT between the index date and the last month of follow-up. Persistence was 
defined as time from initiating index DMT until discontinuation (gap ≥ 60 days), 
receipt of another DMT or end of the 6-month follow-up period. Risk of and time 
to discontinuation were assessed by a Cox proportional hazards model (control-
ling for age, gender and region) and Kaplan-Meier analysis, respectively. Results: 
Using identical criteria, 22,467 PharMetrics patients (fingolimod: n= 1968; IFN/GA: 
n= 20,499) and 49,803 LRx patients (8325 and 41,478, respectively) were selected. 
Proportions of patients discontinuing index DMT were significantly lower for fin-
golimod vs IFN/GA (PharMetrics: 23.1% vs 27.2%; LRx: 26.9% vs 33.4%; p< 0.0001). Risk 
of discontinuation was higher for IFN/GA vs fingolimod (PharMetrics: hazard ratio, 
HR= 1.18; 95%CI: 1.07–1.30, p= 0.0008; LRx: HR= 1.23; 95%CI: 1.17–1.29, p< 0.0001). Time 
to discontinuation was significantly longer for fingolimod vs IFN/GA (PharMetrics: 
p= 0.0005; LRx: p< 0.0001). With more stringent criteria used in PharMetrics, risk 
of discontinuation of IFN/GA vs fingolimod increased (HR= 1.47; 95%CI: 1.24–1.74, 
p< 0.0001). ConClusions: Both data sources provided similar results, supporting 
use of open-source LRx data, which allows access to up-to-date information that 
can improve sample size and statistical power.
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objeCtives: Traditional valuation methods are insensitive to small improvements 
in process and outcome of care. Best-Worst scaling (BWS) was proposed as a sensi-
tive and efficient method to determine the relative value of different treatments 
for the same disease, which would be desirable to estimate cost-effectiveness. The 
study objective was to compare the ability of BWS to differentiate between dif-
ferent treatment alternatives to that of Time Trade Off (TTO) and Visual Analogue 
Scales (VAS). Methods: An online survey was conducted to estimate individual 
values for six different treatments reflecting the real-life options in the treatment 
of Parkinson’s Disease with BWS2, BWS3, TTO and VAS (n= 592). Pearson correla-
tion coefficient was used to examine the strength of linear dependence between 
estimated utility scores. Results: Twenty-seven percent of respondents was not 
willing to trade life years in TTO. Only two percent of the respondent does not 
differentiate between the value of health states with VAS. When non-traders were 
excluded from the analysis, the best case scenario was valued significantly higher 
than the worst case scenario with all methods. Rank reversals among intermedi-
ate alternatives were common. The correlation between utility scores was very 
strong (VAS-BWS2 1,0; VAS-BWS3 0.98; TTO-BWS2 0.99; TTO-BWS3 0.98, BWS2-
BWS3 0.96; P< 0.000, n= 434). ConClusions: The results demonstrate that BWS, 
TTO and VAS can be used to elicit incremental utility gain of small improvements 
in care. However, all methods have limitations. VAS does not result in utilities 
and some respondents do not trade with TTO. While the use of BWS is attractive 
because of its ability to estimate utilities for many different treatment alterna-
tives, its applicability in CEA is limited because BWS utilities are not anchored on 
a 0-1 utility scale. We propose to use TTO to estimate utility for extreme health 
states, and to use BWS to value intermediate health states which differ on process 
characteristics.
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objeCtives: To evaluate health-related quality of life (HRQOL) in migraine based 
on attack frequency by time trade-off method (TTO) in a mixed population sam-
ple consisting of migraneurs and non-migraneurs. Methods: A cross-sectional 
questionnaire survey was designed to measure HRQOL in migraine without aura 
by TTO. A convenience sample was recruited from university students and staff 
regardless of having ever experienced migraine or not. Participants were asked to 
elicit two hypothetical health states characterised by different migraine frequency 
(‘m’: two migraines lasting 4 hours each month and ‘w’: each week) within two 
hypothetical lifetime frames (20 years left to live/lives until the age of 80 years). 
Utilities were calculated for the four tasks (U20m, U80m, U20w, U20w) and com-
pared between subgroups. Results: Altogether 180 respondents were included 
in the analysis. Mean age was 25.6 years (SD 6.4), 71% were female and 61% were 
self-reported migraneurs. Proportion of non-traders varied between 14% and 43% 
